Phase III
The FDA’s decision to approve Purdue’s drug Nalmefene earned mixed reactions, especially as the company is in the middle of lawsuits. Here’s what you need to know.
Not only is this the first approval for a plant-based vaccine, it’s also the first approval for GSK’s adjuvant.
Biopharma companies are continuously working to test new treatments to the market. Here are three clinical updates announced this week, spanning three different continents.
Adagio Therapeutics has appointed current COO David Hering as interim CEO, replacing Tillman Gerngross, Ph.D., who communicated his intention to resign in mid-February.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
AstraZeneca and Sanofi secured accelerated authorization for respiratory syncytial virus (RSV) antibody nirsevimab from the European Medicines Agency.
Marinus Pharmaceuticals reported that its Phase III RAISE trial of IV ganaxolone for status epilepticus will be delayed, thanks to the pandemic.
Public health officials begin to think we’ve turned the corner on the pandemic as new global cases drop 21% last week, the third consecutive week numbers and deaths have declined.
The DSMB endorsed the use of mRNA-1345 for the Phase III ConquerRSV study following positive preliminary Phase II data that demonstrates the vaccine’s safety profile.
Veru’s enobosarm shows good proof of concept data even when 90% of patients have failed first-line therapies.
PRESS RELEASES